OT

OS Therapies Incorporated

OSTX·NYSE

$1.42

-2.1%
HealthcareBiotechnology

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

At a Glance

Live Snapshot
Market Cap$50.00M
EPS-0.5200
P/E Ratio-2.73
Earnings Date03/30/2026

ostx

Interest Expense

Last Annual Value

2.05M

3-Year CAGR

-7%

5-Year CAGR

-66%

10-Year CAGR

-42%

OT

OS Therapies Incorporated Competitors Analysis of Interest Expense

OSTX · NYSE
CompanyInterest Expense
CAGR 3Y
CAGR 5Y
CAGR 10Y
2.05M
-15.9%-4.5%N/A 
CRVO logo
CervoMed Inc.
NASDAQ:CRVO
0.00
N/AN/AN/A
MNOV logo
MediciNova, Inc.
NASDAQ:MNOV
0.00
N/AN/AN/A
0.00
N/AN/AN/A
357.00K
-34.1%N/AN/A
0.00
N/AN/AN/A
5.27M
18.9%N/AN/A
90.00K
-42.9%-23.6%N/A
642.38K
81.4%28.0%N/A
671.00K
77.5%106.2%N/A
283.13B
5561.8%1147.8%229.9%
OT

OS Therapies Incorporated Fair Value Envelope

OSTX · NYSE

Our analysis suggests that OSTX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.42, this represents a potential HIDDEN relative to our calculated worth for OS Therapies Incorporated.

Intrinsic Value
Current Price: $1.42